IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Narasimhaswamy Manjunath and Ulrich Hans von Andrian

Serial No.:

Filed: herewith

For: INHIBITION OF DIFFERENTIATION OF CYTOXIC T-CELLS BY P-SELECTIN LIGAND (PSGL) ANTAGONISTS

Attorney Docket No.: GFN-5339DV

Group Art Unit:

Examiner:

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: July 12, 2001 Mailing Label Number: EL 883 592 402 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Larry Taylor
Name of Person Mailing Paper

Larry Taylor
Signature of Person Mailing Paper

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the application and calculation of the filing fees, please amend the application as follows:

In the Claims:

Please cancel claims 3 and 5-25.

Please amend claims 1, 2, and 4 as follows:

--1. (Amended) A method of inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a P- selectin glycoprotein ligand (PSGL) antagonist.--

--2. (Amended) The method of claim 1, wherein said P- selectin glycoprotein ligand (PSGL) antagonist is selected from the group consisting of a soluble form of PSGL, an antibody directed to PSGL, an antibody directed to sLe_x, an antibody directed to sulfated tyrosine, sLe_x, mimetics which inhibit sLe_x binding and a small molecule inhibitor of PSGL binding.--

--4. (Amended) The method of claim 2, wherein said PSGL antagonist is an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.--

Please add new claims 26-34 as follows:

--26. (New) The method of claim 4, wherein said antibody is a monoclonal antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.--

--27. (New) The method of claim 4, wherein said antibody is administered in a pharmaceutically acceptable formulation.--

--28. (New) A method for treating or ameliorating, in a subject, a disease or condition resulting from differentiation of activated T-cells into cytotoxic lymphocytes comprising administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.--

--29. (New) The method of claim 28, wherein said disease or condition is an autoimmune condition.--

--30. (New) The method of claim 28, wherein said disease or condition is an allergic reaction.--

--31. (New) The method of claim 28, wherein said disease or condition is asthma.--

--32. (New) The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof. --

--33. (New) The method of claim 28, wherein said subject is a mammalian subject.--

--34. (New) The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.--

REMARKS

Claims 3 and 5-25 have been cancelled without prejudice. Claims 1, 2, and 4 have been amended. New claims 26-34 have been added. Accordingly, claims 1, 2, 4, and 26-34 are currently pending. *No new matter has been added.*

Support for the amendments to the claims and the new claims can be found in the specification and claims as originally filed.

Any amendment to or cancellation of the claims is not to be construed as an acquiescence to any of the rejections set forth in the instant Office Action, and was done solely to expedite prosecution of the application. Applicants reserve the right to pursue the subject matter of the claims as originally filed in this or a separate application(s).

Applicants submit herewith a "**Version with Markings to Show Changes Made**," which indicates the specific amendments made the specification.

CONCLUSION

It is respectfully requested that the above amendment be entered. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at the number provided below.

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By ________________________
Amy E. Mandragouras, Esq.
Reg. No. 36,207
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400
(617) 742-4214
Date: July 12, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 1 has been amended as follows:

1. (Amended) A method of inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a P- selectin glycoprotein ligand (PSGL) antagonist.

Claim 2 has been amended as follows:

2. (Amended) The method of claim 1, wherein said P- selectin glycoprotein ligand (PSGL) antagonist is selected from the group consisting of a soluble form of PSGL, an antibody directed to PSGL, an antibody directed to sLe_x, an antibody directed to sulfated tyrosine, sLe_x, mimetics which inhibit sLe_x binding and a small molecule inhibitor of PSGL binding.

Claim 4 has been amended as follows:

4. (Amended) The method of claim 2, wherein said PSGL antagonist is an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.

Claim 26 has been added as follows:

26. (New) The method of claim 4, wherein said antibody is a monoclonal antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.

Claim 27 has been amended as follows:

27. (New) The method of claim 4, wherein said antibody is administered in a pharmaceutically acceptable formulation.

Claim 28 has been amended as follows:

28. (New) A method for treating or ameliorating, in a subject, a disease or condition resulting from differentiation of activated T-cells into cytotoxic lymphocytes comprising administering to said subject a therapeutically effective amount of an antibody directed to P- selectin glycoprotein ligand (PSGL), or a fragment thereof.

Claim 29 has been amended as follows:

29. (New) The method of claim 28, wherein said disease or condition is an autoimmune condition.

Claim 30 has been amended as follows:

30. (New) The method of claim 28, wherein said disease or condition is an allergic reaction.

Claim 31 has been amended as follows:

31. (New) The method of claim 28, wherein said disease or condition is asthma.

Claim 32 has been amended as follows:

32. (New) The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof.

Claim 33 has been amended as follows:

33. (New) The method of claim 28, wherein said subject is a mammalian subject.

Claim 34 has been amended as follows:

34. (New) The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.